BridgeMD
New treatment option for Opioid Use Disorder
Official title Overdose Recovery and Care Access (ORCA) Qualitative Stakeholder Interviews and County-level Data
ClinicalTrials.gov ID: NCT06768814
What this study is testing
- What it's testing
- The study is a quasi-experimental investigation of a sub-acute stabilization center (SASC) for people who have had or are at risk for having an opioid overdose and have an encounter with Seattle Fire Department emergency medical services (EMS) in Seattle, WA. Those transported to the SASC are the intervention participants and two comparison groups will be utilized: eligible Seattle EMS patients who opt not to go to the SASC and King County residents, outside of Seattle, who meet the same eligibility criteria.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Verbally consents to transfer of care to SASC.
- Awake and oriented to person and place, with no significant deficits in mental status or neurological function.
- Age \>=18
- Patent airway and effective respirations with adequate oxygenation.
- Stable heart rate and blood pressure, with no evidence of cardiac arrhythmias or other significant cardiovascular disfunction.
You likely can't join if
- \- People under 18 and who do not meet SASC admission criteria will be excluded.
See the full eligibility criteria
- Verbally consents to transfer of care to SASC.
- Awake and oriented to person and place, with no significant deficits in mental status or neurological function.
- Age \>=18
- Patent airway and effective respirations with adequate oxygenation.
- Stable heart rate and blood pressure, with no evidence of cardiac arrhythmias or other significant cardiovascular disfunction.
- Vitals:
- Heart rate: 45-130
- Blood pressure: systolic 95-190, diastolic 50-120
- Respiratory rate: 10-24
- SpO2: \>92 on room air or supplemental O2 via nasal cannula.
- SpO2 \<92% with supplemental O2 requires ED transfer.
- EtCO2: \<50
- Temperature: 95.5-100.3 F
- Blood glucose (if indicated): 60-300
- No signs of head trauma:
- Dizziness or loss of balance
- Blurred vision or double vision
- Sensitivity to light or noise
- Seizures or convulsions
- Weakness or numbness in the arms or legs
- Persistent or worsening headache
- CSF or blood leaking from the nose or ears
- Unequal pupils or pupils that are slow to react to light.
- No signs of other traumatic injury or medical needs requiring immediate treatment.
- No signs of respiratory infection. Screen for COVID-19. See COVID-19 Screening protocol.
- \- People under 18 and who do not meet SASC admission criteria will be excluded.
The study team makes the final eligibility decision.
Where it's taking place
- Seattle, Washington, United States
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Seattle, Washington, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.